IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors

Dr Bindra speaks with ecancer at AACR 2017 about the determination of PARP inhibitor sensitivity in brain tumour cells with IDH mutations

He describes how, from screening of a CRISPR-Cas9 model of mutant IDH cells, synthetic lethality with PARP inhibitory therapy was uncovered.

Dr Bindra highlights the current approval of PARP inhibitors in other indications, and outlines upcoming trials to further explore treatment options.